US FDA starts to assess Celltrion’s Herzuma approval
Celltrion will resume the U.S. approval acquisition process as completing submission of additional documents to the FDA for ‘Herzuma,’ an antibody biosimilar for breast cancer.
Celltrion announced the company officially submitted additional revision documents for product approval of Herzuma(CT-P...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.